Should Patients With High-Risk or Transformed Myelodysplastic Syndrome Proceed Directly to Allogeneic Transplant Without Prior Cytoreduction by Remission-Induction Chemotherapy or Hypomethylating Agent Therapy?

被引：6

作者：

de Witte, Theo M. ^{[1
]}

Bowen, David ^{[2
]}

Robin, Marie ^{[3
]}

Malcovati, Luca ^{[4
]}

Mufti, Ghulam ^{[5
]}

Niederwieser, Dietger ^{[6
]}

Yakoubagha, Ibrahim ^{[7
]}

Kroeger, Nicolaus ^{[8
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, NL-6500 HB Nijmegen, Netherlands

[2] St Jamess Inst Oncol, Leeds, W Yorkshire, England

[3] Hop St Louis, St Louis, France

[4] Univ Pavia, Policlin San Matteo, I-27100 Pavia, Italy

[5] Kings Coll Hosp London, London, England

[6] Univ Hosp Leipzig, Leipzig, Germany

[7] Ctr Hosp Reg Univ Lille, Lille, France

[8] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2014年 / 14卷

关键词：

Allogeneic hematopoietic stem cell transplantation; Cytoreduction with hypomethylating agents; Cytoreduction with intensive chemotherapy; High-Risk myelodysplastic syndrome; Transformed myelodysplastic syndrome; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; HLA-IDENTICAL SIBLINGS; BONE-MARROW-TRANSPLANTATION; PERIPHERAL-BLOOD; SCORING SYSTEM; UNRELATED DONORS; SYNDROMES MDS; OLDER; AZACITIDINE;

D O I：

10.1016/j.clml.2014.06.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The selection of a treatment strategy before allogeneic hematopoietic Stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

引用

页码：S42 / S45

页数：4

共 28 条

[1] Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors [J].

Anasetti, Claudio ;

Logan, Brent R. ;

Lee, Stephanie J. ;

Waller, Edmund K. ;

Weisdorf, Daniel J. ;

Wingard, John R. ;

Cutler, Corey S. ;

Westervelt, Peter ;

Woolfrey, Ann ;

Couban, Stephen ;

Ehninger, Gerhard ;

Johnston, Laura ;

Maziarz, Richard T. ;

Pulsipher, Michael A. ;

Porter, David L. ;

Mineishi, Shin ;

McCarty, John M. ;

Khan, Shakila P. ;

Anderlini, Paolo ;

Bensinger, William I. ;

Leitman, Susan F. ;

Rowley, Scott D. ;

Bredeson, Christopher ;

Carter, Shelly L. ;

Horowitz, Mary M. ;

Confer, Dennis L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (16) :1487-1496

[2] Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies [J].

Damaj, Gandhi ;

Duhamel, Alain ;

Robin, Marie ;

Beguin, Yves ;

Michallet, Mauricette ;

Mohty, Mohamad ;

Vigouroux, Stephane ;

Bories, Pierre ;

Garnier, Alice ;

El Cheikh, Jean ;

Bulabois, Claude-Eric ;

Huynh, Anne ;

Bay, Jacques-Olivier ;

Legrand, Faeyzeh ;

Deconinck, Eric ;

Fegueux, Nathalie ;

Clement, Laurence ;

Dauriac, Charles ;

Maillard, Natacha ;

Cornillon, Jerome ;

Ades, Lionel ;

Guillerm, Gaelle ;

Schmidt-Tanguy, Aline ;

Marjanovic, Zora ;

Park, Sophie ;

Rubio, Marie-Therese ;

Marolleau, Jean-Pierre ;

Garnier, Federico ;

Fenaux, Pierre ;

Yakoub-Agha, Ibrahim .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :4533-4540

[3] Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS [J].

de Witte, T ;

Suciu, S ;

Verhoef, G ;

Labar, B ;

Archimbaud, E ;

Aul, C ;

Selleslag, D ;

Ferrant, A ;

Wijermans, P ;

Mandelli, F ;

Amadori, S ;

Jehn, U ;

Muus, P ;

Boogaerts, M ;

Zittoun, R ;

Gratwohl, A ;

Zwierzina, H ;

Hagemeijer, A ;

Willemze, R .

BLOOD, 2001, 98 (08) :2326-2331

[4] Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial [J].

de Witte, Theo ;

Hagemeijer, Anne ;

Suciu, Stefan ;

Belhabri, Amin ;

Delforge, Michel ;

Kobbe, Guido ;

Selleslag, Dominik ;

Schouten, Harry C. ;

Ferrant, Augustin ;

Biersack, Harald ;

Amadori, Sergio ;

Muus, Petra ;

Jansen, Joop H. ;

Hellstrom-Lindberg, Eva ;

Kovacsovics, Tibor ;

Wijermans, Pierre ;

Ossenkoppele, Gert ;

Gratwohl, Alois ;

Marie, Jean-Pierre ;

Willemze, Roel .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (10) :1754-1761

[5] Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation.: Results from the Spanish registry [J].

del Cañizo, MC ;

Martínez, C ;

Conde, E ;

Vallejo, C ;

Brunet, S ;

Sanz, G ;

Mateos, MV .

BONE MARROW TRANSPLANTATION, 2003, 32 (10) :987-992

[6] Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome [J].

Deschler, Barbara ;

Ihorst, Gabriele ;

Platzbecker, Uwe ;

Germing, Ulrich ;

Maerz, Eva ;

de Figuerido, Marcelo ;

Fritzsche, Kurt ;

Haas, Peter ;

Salih, Helmut R. ;

Giagounidis, Aristoteles ;

Selleslag, Dominik ;

Labar, Boris ;

de Witte, Theo ;

Wijermans, Pierre ;

Luebbert, Michael .

HAEMATOLOGICA, 2013, 98 (02) :208-216

[7]

Dreg HJ, 2002, BLOOD, V100, P1201

[8]

Dreg HJ, 2000, BLOOD, V95, P1188

[9] Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy [J].

Estey, E ;

Thall, P ;

Beran, M ;

Kantarjian, H ;

Pierce, S ;

Keating, M .

BLOOD, 1997, 90 (08) :2969-2977

[10] Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS [J].

Gerds, Aaron T. ;

Gooley, Ted A. ;

Estey, Elihu H. ;

Appelbaum, Frederick R. ;

Deeg, H. Joachim ;

Scott, Bart L. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (08) :1211-1218

← 1 2 3 →